A phase 2, open label, 2Arm, response rate study of talazoparib in men with DNA repair defects and metastatic castration resistant prostate cancer who previously received taxane based chemotherapy and progressed on at least 1 novel hormonal agent
- Kwan, Edmond (Primary Chief Investigator (PCI))
Project: Research